AngenMed
1 known investors
AngenMed develops neoantigen-targeting cell-based cancer immunotherapies, including dendritic cell vaccines and neoantigen-specific T cell products personalized to each patient's tumor mutations. The company operates in the biotech and cancer therapeutics space, using tumor sequencing to identify neoantigens and manufacture DC and T-cell products.
BiotechDeep TechHealthtech
Investors · 1
Frequently asked questions
- What does AngenMed do?
- AngenMed develops neoantigen-targeting cell-based cancer immunotherapies, including dendritic cell vaccines and neoantigen-specific T cell products personalized to each patient's tumor mutations. The company operates in the biotech and cancer therapeutics space, using tumor sequencing to identify neoantigens and manufacture DC and T-cell products.
- Who are AngenMed's investors?
- AngenMed's investors include Maxpro Ventures.